Intravenous Heparin: Indications, Dosing, and Monitoring Guidelines

Clinical Indications

IV heparin is recommended as the anticoagulant of choice for acute thrombotic emergencies (e.g., deep‑vein thrombosis, pulmonary embolism, unstable angina, NSTEMI) because it achieves therapeutic anticoagulation within minutes and can be rapidly reversed if bleeding occurs 1.
For acute venous thromboembolism, early therapeutic anticoagulation with IV heparin directly prevents recurrent embolism and lowers mortality (Class I, Level A evidence) 2.
In patients with unstable angina or non‑ST‑segment‑elevation myocardial infarction, adding IV heparin to aspirin reduces cardiovascular death and subsequent myocardial infarction by approximately 30 % compared with aspirin alone (Class I, Level A) 3.
When IV heparin is combined with thrombolytic agents or GP IIb/IIIa inhibitors, the American Heart Association advises dose reduction (with maximum caps) to mitigate the heightened bleeding risk (Class IIa, Level B) 4.
Moderate‑dose subcutaneous heparin (≈12,500 U every 12 h) lowers the incidence of mural thrombosis after anterior‑wall myocardial infarction by 58–72 %, supporting the use of IV heparin when rapid, reliable anticoagulation is required 2.

The American College of Chest Physicians recommends an initial IV bolus of 80 U/kg followed by a continuous infusion of 18 U/kg/h, targeting an activated partial thromboplastin time (aPTT) 1.5–2.5 × the control value (Class I, Level A) 5.
Weight‑based dosing is essential; fixed‑dose regimens (e.g., 5,000 U bolus + 1,000 U/h) frequently produce subtherapeutic anticoagulation in the first 24 h and are associated with a 25 % recurrence rate of thrombotic events (Class III, Level B) 5.
For percutaneous coronary intervention, a loading dose of 100–175 U/kg is advised, aiming for an activated clotting time (ACT) >300–350 s (or 70 U/kg with GP IIb/IIIa inhibitors targeting ACT >200 s) (Class I, Level B) 6.
Therapeutic anticoagulation should be maintained for a minimum of 5 days, with overlap to oral vitamin K antagonists until the international normalized ratio (INR) is ≥2.0 for at least 24 h (Class IIa, Level C) 7.

Randomized trials show that patients who achieve therapeutic aPTT within 24 h experience markedly lower recurrence of VTE (2 % vs 25 %) and reduced mortality compared with those whose therapeutic level is delayed (Level A) 5.
In head‑to‑head comparisons, identical total daily heparin doses delivered by continuous IV infusion result in significantly fewer recurrent thrombotic events than intermittent subcutaneous injections, owing to sustained therapeutic plasma concentrations (Level A) 5.

Subcutaneous heparin fails to provide adequate anticoagulation during the first 24 h unless very high doses (≈17,500 U) are used, whereas IV infusion delivers immediate, titratable therapeutic levels (Level B) 2.
Heparin’s nonlinear, saturable clearance necessitates continuous IV infusion to maintain stable anticoagulation, as intermittent subcutaneous dosing leads to fluctuating troughs and peaks (Level B) 5.

aPTT should be measured every 4–6 hours during initiation of therapy and then daily once the target range is stable, allowing precise dose adjustments and balancing efficacy against bleeding risk (Class I, Level B) 1.
Implementation of weight‑based nomograms with standardized adjustment algorithms improves clinical outcomes compared with empiric dosing practices (Class IIa, Level B) 2.

Heparin prevents extension of existing deep‑vein thrombosis or pulmonary embolism and lowers recurrent thromboembolism from ≈ 25 % to ≈ 2 % when therapeutic anticoagulation is achieved within the first 24 hours. 8
Patients who reach therapeutic aPTT within 24 hours experience a recurrence rate of 2 % (versus 25 % with delayed therapeutic levels) and demonstrate reduced mortality. 9

Low‑dose subcutaneous heparin (5,000 U every 8–12 h) effectively prevents postoperative DVT and PE in individuals undergoing major abdominothoracic surgery or other high‑risk procedures. 8, 10

In unstable angina or non‑ST‑segment elevation myocardial infarction without thrombolytic therapy, an IV bolus of 5,000 U followed by a continuous infusion of 32,000 U per 24 h (adjusted to maintain therapeutic aPTT) reduces cardiovascular death and subsequent MI by roughly 30 % compared with aspirin alone. 8, 10, 11
After fibrinolytic therapy for acute MI, a reduced heparin regimen—60 U/kg bolus (maximum 4,000 U) followed by 12 U/kg/h infusion (maximum 1,000 U/h)—decreases bleeding risk while preserving anticoagulant effect. 9

Weight‑based dosing (80 U/kg bolus then 18 U/kg/h infusion) is essential for VTE treatment; fixed‑dose regimens yield subtherapeutic anticoagulation in the first 24 h and are associated with a 25 % recurrence rate. 9
Fixed‑dose heparin regimens for acute VTE consistently fail to achieve early therapeutic anticoagulation and increase the risk of recurrent thromboembolism. 9
The therapeutic aPTT target is 1.5–2.5 × control, corresponding to heparin plasma concentrations of 0.2–0.4 U/mL or anti‑factor Xa activity of 0.30–0.70 U/mL. 8, 11

Daily platelet‑count monitoring is advised because heparin‑induced thrombocytopenia occurs in up to 5 % of patients receiving unfractionated heparin. 12